Details

Autor(en) / Beteiligte

• LANGERAK, A. W
• GROENEN, Pjta
• DELFAU-LARUE, M.-H
• DISS, T
• EVANS, Pas
• GAMEIRO, P
• GARCIA SANZ, R
• GONZALEZ, D
• GRAND, D
• HAKANSSON, A
• HUMMEL, M
• LIU, H
• BRÜGGEMANN, M
• LOMBARDIA, L
• MACINTYRE, E. A
• MILNER, B. J
• MONTES-MORENO, S
• SCHUURING, E
• SPAARGAREN, M
• HODGES, E
• DONGEN, Jjm Van
• BELDJORD, K
• BELLAN, C
• BONELLO, L
• BOONE, E
• CARTER, G. I
• CATHERWOOD, M
• DAVI, F

Titel

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

Ist Teil von

• Leukemia, 2012-10, Vol.26 (10), p.2159-2171

Ort / Verlag

Avenel, NJ: Nature Publishing Group

Erscheinungsjahr

2012

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been standardized and has consequently become technically feasible in a routine diagnostic setting. Standardization of the pre-analytical and post-analytical phases is now essential to prevent misinterpretation and incorrect conclusions derived from clonality data. As clonality testing is not a quantitative assay, but rather concerns recognition of molecular patterns, guidelines for reliable interpretation and reporting are mandatory. Here, the EuroClonality (BIOMED-2) consortium summarizes important pre- and post-analytical aspects of clonality testing, provides guidelines for interpretation of clonality testing results, and presents a uniform way to report the results of the Ig/TCR assays. Starting from an immunobiological concept, two levels to report Ig/TCR profiles are discerned: the technical description of individual (multiplex) PCR reactions and the overall molecular conclusion for B and T cells. Collectively, the EuroClonality (BIOMED-2) guidelines and consensus reporting system should help to improve the general performance level of clonality assessment and interpretation, which will directly impact on routine clinical management (standardized best-practice) in patients with suspected lymphoproliferations.